论文部分内容阅读
随机、交叉、双盲观察沙美特罗对３０对哮喘患者的疗效，２次／ｄ，结果：两组临床症状计分明显下降（Ｐ＜０．０５），但沙美特罗组起效慢，对夜间症状效果佳，优于沙丁胺醇。两组ＦＥＶ１和ＦＥＶ１．０％比治疗前明显提高（Ｐ＜０．０１，Ｐ＜０．０５）；ＰＥＦＲ也明显增加（Ｐ＜０．０１，Ｐ＜０．０５）。沙美特罗组晚上ＰＥＦＲ增加明显，缩小了日间变异。两组均未出现血压、心率和体重的显著变化，未见心慌、手抖及肝肾功能等异常。结果表明，沙美特罗能缓解症状，改善肺功能，但起效慢，不适合急诊缓解症状用，较适合作为夜间症状重的哮喘患者的基础用药
The effect of salmeterol on 30 pairs of asthmatic patients was observed by randomized, double-blind and double-blind observation. Results: The scores of clinical symptoms were significantly decreased in the two groups (P <0.05) Good nighttime symptoms, better than salbutamol. FEV1 and FEV1.0% in both groups were significantly higher than those before treatment (P <0.01, P <0.05); PEFR also increased significantly (P <0.01, P <0.05). In the salmeterol group, the PEFR increased significantly at night, which reduced the daytime variation. No significant changes in blood pressure, heart rate and weight occurred in either group. No palpitation, hand tremor, liver and kidney function abnormalities were observed. The results show that salmeterol can relieve symptoms and improve lung function, but the onset is slow, not suitable for emergency treatment to relieve symptoms, is more suitable as a basis for the nighttime symptoms of asthma patients with medication